Fig. 2.

GluCEST Contrast and gadolinium enhancing tumour.

FLAIR, T₁ weighted imaging with and without contrast and co-registered GluCEST imaging are presented for patient 4. WHO grade II oligodendroglioma IDH-mutant, 1p/19q codeleted, subsequent radiological progression and adjuvant therapy (temozolamide, radiotherapy). (A) 3 T FLAIR images in the axial GluCEST acquisition plane, tumour identified by white arrows. (B) 3 T T1 weighted images without gadolinium contrast in the axial GluCEST acquisition plane. (C) 3 T T1 weighted images with gadolinium contrast in the axial GluCEST acquisition plane with evidence of nodular, wispy mesial contrast enhancement (red arrows). (D) 3 T T1 weighted images with gadolinium co-registered with GluCEST contrast maps. Increased GluCEST contrast in a region overlapping, but extending beyond the area of gadolinium enhancement (black arrows).